Details
Stereochemistry | RACEMIC |
Molecular Formula | C21H29ClO6S |
Molecular Weight | 444.969 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H](COC1=CC=CC(Cl)=C1)CS[C@@H]2[C@@H](O)C[C@@H](O)[C@H]2C\C=C/CCCC(O)=O
InChI
InChIKey=KFUDFIMHDRJVLV-OZCLATTGSA-N
InChI=1S/C21H29ClO6S/c22-14-6-5-7-16(10-14)28-12-15(23)13-29-21-17(18(24)11-19(21)25)8-3-1-2-4-9-20(26)27/h1,3,5-7,10,15,17-19,21,23-25H,2,4,8-9,11-13H2,(H,26,27)/b3-1-/t15-,17-,18-,19+,21+/m1/s1
Luprostiol is a synthetic prostaglandin F2α and is a luteolytic agent. It is used for estrus control and termination of pregnancy in mares. In cattle Luprostiol is indicated for:
- Oestrus regulation / oestrus synchronization;
- Treatment of suboestrus;
- Induction of abortion;
- Induction of parturition;
- Treatment of pyometra, chronic endometritis and fetal mummification.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Equestrolin Approved UseLuprostiol is indicated for 1) estrus control and 2) termination of pregnancy in mares under the following conditions:
Estrus Control: Luprostiol is effective as a luteolysin and may be used to regress a functional, progesterone producing corpus luteum, subsequently inducing estrus, ovulation and normal conception in breeding mares under the following conditions:
Estrus Control in Normal Cycling and Transitional Phase Mares:
Normal cycling mares that demonstrate estrus activity may be treated to shorten the estrous cycle. Treatment should be given during the diestrus period when functional corpora lutea are present.
Mares displaying estrous cycles, albeit erratic, may be treated if mature corpora lutea are present to shorten and/or reinitiate the estrous cycle.
Estrus Control in Postpartum Mares:
Postpartum mares that exhibit an overt foal heat but are not bred at this heat, in order to avoid reduced fertility, may be treated six to 12 days after the foal heat ovulation to attempt an early return to estrus ("second" foal heat) and subsequent breeding opportunity.
Lactating mares that do not exhibit a foal heat and that are considered to be in lactational anestrus may be treated approximately 21 days postpartum in order to initiate estrus cyclicity.
Estrus Control in Mares With Persistent Corpora Lutea:
Mares not cycling due to a persistent corpus luteum (CL) may be treated to terminate functional luteal tissue. This would include:
mares considered pseudopregnant (i.e., bred and determined not to be pregnant but displaying signs of pregnancy as a result of persistent CL activity).
mares in clinical anestrus (i.e., not cycling during the breeding season due to persistent CL activity).
mares that have lost a conceptus during early gestation and that have not recycled due to persistent CL activity.
maiden and barren mares in extended periods of diestrus due to persistent CL activity.
Termination of Pregnancy
The luteolytic activity of luprostiol is also effective for the induction of abortion in mares pregnant for 36 days or less. Launch Date1990 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24268486
Luprostiol (1 ug/mL) induced DNA defragmentation and caspase-3 activity in cultured bovine luteal cells, inhibiting cell viability.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 522.1290
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
||
|
WHO-VATC |
QG02AD91
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
||
|
NCI_THESAURUS |
C78568
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
67110-79-6
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
6441712
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
HWR60H5GZB
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
2583725
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
4600
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
m6940
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000082272
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
SUB08620MIG
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
HWR60H5GZB
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
C66042
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
DB11425
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL2218923
Created by
admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY